A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer

NCT02359058 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Stomach Neoplasms

Interventions

DRUG: Ramucirumab
DRUG: Capecitabine
DRUG: Cisplatin
DRUG: S-1
DRUG: Oxaliplatin

Sponsor

Eli Lilly and Company